Citius Oncology, Inc. CTOR Gain On Sale Of New Jersey Net Operating Losses
Other financials
Where this comes from
Reported directly by Citius Oncology, Inc. in its filing.
Tagged under the XBRL concept ctor:GainOnSaleOfNewJerseyNetOperatingLosses.
The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about Citius Oncology, Inc.'s gain on sale of new jersey net operating losses.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Citius Oncology, Inc.'s gain on sale of new jersey net operating losses?
- Citius Oncology, Inc. (CTOR) reported gain on sale of new jersey net operating losses of $1.76M in Q1 2026.